An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer

Gene Therapy

Volumn 6, Issue 10, 1999, Pages 1721-1727

  Binley, K ^a   Iqball, S ^a   Kingsman, A ^a,b   Kingsman, S ^a,b   Naylor, S ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Cancer; Cardiovascular disease; Hypoxia

Indexed keywords

COBALT CHLORIDE; DEFEROXAMINE; TRANSCRIPTION FACTOR; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BREAST CARCINOMA; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL TYPE; CONTROLLED STUDY; DNA SEQUENCE; FIBROSARCOMA; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYPOXEMIA; HYPOXIA; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; SKELETAL MUSCLE;

ADENOVIRIDAE; ANIMALS; ANOXIA; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; ISCHEMIA; MICE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032866070     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301001     Document Type: Article

References (44)

1. Dmitriev I et al. An adenovirus vector with genetically modifed fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
2. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-6846.
3. Wickham TJ et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
4. Kim S et al. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest 1997; 100: 1006-1014.
5. Inesi G et al. Cell-specific promoter in adenovirus vector for transgenic expression of SERCA1 ATPase in cardiac myocytes. Am J Physiol 1998; 274: C645-C653.
6. Bui LA et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 1997; 8: 2173-2182.
7. Dusetti NJ et al. The pancreatitis-associated protein I promoter allows targeting to the pancreas of a foreign gene, whose expression is up-regulated during pancreatic inflammation. J Biol Chem 1997; 272: 5800-5804.
8. Franz WM, Rothmann T, Frey N, Katus HA. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res 1997; 35: 560-566.
9. Larochelle N et al. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer. Gene Therapy 1997; 4: 465-472.
10. Dachs GU, Stratford IJ. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer 1996; 74: S126-S132.
11. Pugh CW et al. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc Natl Acad Sci USA 1991; 88: 10553-10557.
12. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88: 5680-5684.
13. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Circ Res 1995; 77: 638-643.
14. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-6500.
15. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxiainducible factor 1. J Biol Chem 1994; 269: 23757-23763.
16. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 268: 21513-21518.
17. Kallio PJ et al. Activation of hypoxia-inducible factor 1 alpha: post-transcriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997; 94: 5667-5672.
18. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
19. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
20. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilisation of its α subunit. J Biol Chem 1996; 271: 32253-32259.
21. Jiang BH, Semenza GL, Bower C, Marti HH. Hypoxia-inducible factor 1 levels vary over a physiologically relevant range of oxygen tension. Am J Physiol 1996; 271: 1172-1180.
22. Vaupel PW. Oxygenation of solid tumours. In: Teicher BA (ed). Drug Resistance in Oncology. Marcel Dekker: New York, 1993, pp 53-85.
23. Rothschild BM, Alfonse TM. Pathogenesis of rheumatoid arthritis: a vascular hypothesis. Semin Arth Rheum 1982; 12: 11-31.
24. Baumgartner I et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with chronic limb ischemia. Circulation 1998; 97: 1114-1123.
25. Dachs GU et al. Targeting gene expression to hypoxic tumour cells. Nature Med 1997; 3: 515-520.
26. Rinsch C et al. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 1997; 8: 1881-1889.
27. Prentice H et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc Res 1997; 35: 567-574.
28. Setoguchi Y, Danel C, Crystal RG. Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 1994; 84: 2946-2953.
29. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 9: 1412-1415.
30. Marshall DJ, Leiden JM. Recent advances in skeletal-muscle-based gene therapy. Curr Opin Genet Dev 1998; 8: 360-365.
31. 2 tension measurements. Cancer Res 1991; 51: 3316-3322.
32. Brizel DM et al. Tumor hypoxia affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
33. Blatt J. Desferoxamine in children with recurrent neuroblastoma. Anticancer Res 1994; 14: 2109-2112.
34. Donfrancesco A et al. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur J Cancer 1995; 31A: 612-615.
35. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol 1998; 101: 399-406.
36. Olivieri NF et al. Long term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New Engl J Med 1998; 339: 417-423.
37. Agani F, Semenza GL. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol 1998; 54: 749-754.
38. Zelzer E et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J 1998; 17: 5085-5094.
39. Wickham TJ, Roelvink DW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotech 1996; 14: 1570-1573.
40. Shi Q, Wang Y, Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther 1997; 8: 403-410.
41. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for generic therapy. Hum Gene Ther 1997; 8: 803-815.
42. Rossi F, Blau H. Recent advances in inducible gene expression systems. Curr Opin Biotechnol 1998; 9: 451-456.
43. Svensson EC, Tripathy SK, Leiden JM. Muscle-based gene therapy: realistic possibilities for the future. Mol Med Today 1996; 2: 166-172.
44. Lowenstein PR, Enquist LW. Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. John Wiley: New York. 1996.